Literature DB >> 7706822

Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae-infected lung tissue.

I A Bakker-Woudenberg1, M T ten Kate, L E Stearne-Cullen, M C Woodle.   

Abstract

Polymer (PEG-PE)-coated liposomes exhibit prolonged circulation time in blood and substantial localization in Klebsiella pneumoniae-infected lung tissue in rats. Therefore, to determine the therapeutic effect, gentamicin and ceftazidime were entrapped in these liposomes and administered to rats experimentally infected with pneumonia: Relatively high and sustained concentrations of liposome-associated antibiotic in blood were observed. Compared with antibiotics alone, one dose of liposome-entrapped gentamicin or ceftazidime increased the therapeutic effect of the drugs, survival of rats, and bacterial killing in lungs. One dose of liposome-entrapped ceftazidime was as effective as a continuous 2-day infusion of nonentrapped ceftazidime. Since antibiotic-containing liposomes are stable during circulation and liposome-entrapped ceftazidime and gentamicin have low bactericidal activity in vitro, the superior therapeutic effect of the liposome-encapsulated antibiotics results from localization and subsequent degradation of liposomes and the resulting release of entrapped antibiotic at the infection site.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7706822     DOI: 10.1093/infdis/171.4.938

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Administration of liposomal agents and blood clearance capacity of the mononuclear phagocyte system.

Authors:  E W van Etten; M T ten Kate; S V Snijders; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

2.  Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella pneumoniae pneumonia in relation to impaired host defense and low bacterial susceptibility to gentamicin.

Authors:  R M Schiffelers; G Storm; M T ten Kate; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  Antibacterial efficacy of gentamicin encapsulated in pH-sensitive liposomes against an in vivo Salmonella enterica serovar typhimurium intracellular infection model.

Authors:  C Cordeiro; D J Wiseman; P Lutwyche; M Uh; J C Evans; B B Finlay; M S Webb
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Efficacy of liposomal amphotericin B with prolonged circulation in blood in treatment of severe pulmonary aspergillosis in leukopenic rats.

Authors:  E W Van Etten; L E Stearne-Cullen; M ten Kate; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

5.  Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.

Authors:  I A Bakker-Woudenberg; M T ten Kate; L Guo; P Working; J W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

6.  Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue.

Authors:  R M Schiffelers; G Storm; I A Bakker-Woudenberg
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

7.  Ciprofloxacin in polyethylene glycol-coated liposomes: efficacy in rat models of acute or chronic Pseudomonas aeruginosa infection.

Authors:  Irma A J M Bakker-Woudenberg; Marian T ten Kate; Luke Guo; Peter Working; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 8.  Liposomal drug formulations. Rationale for development and what we can expect for the future.

Authors:  T M Allen
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

9.  Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome).

Authors:  R M Fielding; R O Lewis; L Moon-McDermott
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

10.  Improvement of the pharmacokinetics and in vivo antibacterial efficacy of a novel type IIa topoisomerase inhibitor by formulation in liposomes.

Authors:  Adam B Shapiro; Joseph Newman; Kosalaram Goteti; Marie-Eve Beaudoin; Rane Harrison; Sussie Hopkins; Nikunj Agrawal; Olga Rivin
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.